banner
发布时间：2019-07-09 00:00:00
全部分类
论文
- 分类：科学研究
- 发布时间：2019-05-29 00:00:00
- 访问量：0
概要:
详情
Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cellmalignancies.
1,2, 1,2, 1,2, 1,2, 1,2, 1,2, 3,4, 4, 1,2, 1,2, 1,2, 1,2, 1,2, 1,2,1,2, 1,2, 1,2, 1,2, 1,2, 5, 1,2, 3,4, 1,2, 1,2.
2020 Jan 2;135(1):17-27. doi: 10.1182/blood.2019000017.
Anti-CD30 chimeric antigen receptor T cell therapy for relapsed/refractory CD30+ lymphoma patients.
1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 1, 2, 3.
2020 Jan 23;10(1):8. doi: 10.1038/s41408-020-0274-9.
Entecavir Prophylaxis for Hepatitis B Virus Reactivation in Patients with CAR T-cell Therapy.
1, 2, 3, 4, 5, 4, 1, 1, 1, 6, 6, 1, 5, 7, 5, 5.
2020 Apr 14. pii: blood.2020004907. doi: 10.1182/blood.2020004907.
Efficacy and Toxicity for CD22/CD19 Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed/Refractory Aggressive B-cell Lymphoma Involving the Gastrointestinal Tract
Chen Zeng 1, Jiali Cheng 1, Tongjuan Li 1, Jin Huang 1, Chunrui Li 1, Lijun Jiang 1, Jue Wang 1, Liting Chen 1, Xia Mao 1, Li Zhu 1, Yaoyao Lou 1, Jianfeng Zhou 1, Xiaoxi Zhou 2
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13
Long‐term outcomes of relapsed/refractory double‐hit lymphoma (r/r DHL) treated with CD19/22 CAR T‐cell cocktail therapy
DOI: 10.1002/ctm2.176
; ;
A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia
扫二维码用手机看
